Nimodipine inhibits inflow of Ca ions into cells by blocking Ca channels or select voltage-sensitive areas resulting in relaxation of vascular smooth muscle and myocardium during depolarisation. Nimodipine has greater action on the cerebral vessels because of its high lipophilicity.
(in Tablet form)
Adult: Initial dose is 60 mg in every four hours interval for 21 consecutive days, preferably not less than one hour before or two hours after meals.
Oral Nimodipine therapy should be commence within 96 hours of the subarachnoid hemorrhage.
Use in Pediatric Patients: While there is no specific information on use of this medication in pediatric patients.
Manufacturer: Square Pharmaceutical Ltd.